10x Genomics, Inc. (TXG) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
10x Genomics, Inc. (TXG) Bundle
Evaluate 10x Genomics, Inc.'s financial outlook like an expert! This (TXG) DCF Calculator provides pre-filled financial data and offers full flexibility to modify revenue growth, WACC, margins, and other essential assumptions to align with your projections.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 245.9 | 298.8 | 490.5 | 516.4 | 618.7 | 790.1 | 1,008.8 | 1,288.2 | 1,644.9 | 2,100.3 |
Revenue Growth, % | 0 | 21.53 | 64.13 | 5.28 | 19.81 | 27.69 | 27.69 | 27.69 | 27.69 | 27.69 |
EBITDA | -20.9 | -513.8 | -24.6 | -128.5 | -205.1 | -271.1 | -346.1 | -441.9 | -564.3 | -720.6 |
EBITDA, % | -8.49 | -171.92 | -5.01 | -24.88 | -33.15 | -34.31 | -34.31 | -34.31 | -34.31 | -34.31 |
Depreciation | 7.1 | 19.0 | 28.3 | 33.0 | 43.6 | 44.9 | 57.4 | 73.3 | 93.6 | 119.5 |
Depreciation, % | 2.87 | 6.36 | 5.76 | 6.39 | 7.05 | 5.69 | 5.69 | 5.69 | 5.69 | 5.69 |
EBIT | -28.0 | -532.8 | -52.8 | -161.5 | -248.7 | -305.9 | -390.6 | -498.8 | -636.9 | -813.3 |
EBIT, % | -11.37 | -178.28 | -10.77 | -31.27 | -40.2 | -38.72 | -38.72 | -38.72 | -38.72 | -38.72 |
Total Cash | 424.2 | 663.6 | 587.4 | 430.0 | 388.7 | 704.9 | 900.0 | 1,149.3 | 1,467.5 | 1,873.9 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | 33.4 | 51.2 | 85.3 | 104.2 | 114.8 | 137.2 | 175.2 | 223.7 | 285.6 | 364.7 |
Account Receivables, % | 13.57 | 17.14 | 17.38 | 20.18 | 18.56 | 17.37 | 17.37 | 17.37 | 17.37 | 17.37 |
Inventories | 15.3 | 30.0 | 60.0 | 81.6 | 73.7 | 88.8 | 113.4 | 144.7 | 184.8 | 236.0 |
Inventories, % | 6.21 | 10.02 | 12.23 | 15.81 | 11.91 | 11.24 | 11.24 | 11.24 | 11.24 | 11.24 |
Accounts Payable | 13.0 | 4.7 | 17.4 | 21.6 | 15.7 | 27.1 | 34.6 | 44.2 | 56.4 | 72.0 |
Accounts Payable, % | 5.3 | 1.58 | 3.54 | 4.18 | 2.54 | 3.43 | 3.43 | 3.43 | 3.43 | 3.43 |
Capital Expenditure | -42.8 | -38.4 | -101.3 | -131.7 | -49.5 | -133.3 | -170.3 | -217.4 | -277.6 | -354.5 |
Capital Expenditure, % | -17.39 | -12.85 | -20.65 | -25.5 | -8 | -16.88 | -16.88 | -16.88 | -16.88 | -16.88 |
Tax Rate, % | -2.55 | -2.55 | -2.55 | -2.55 | -2.55 | -2.55 | -2.55 | -2.55 | -2.55 | -2.55 |
EBITAT | -28.2 | -541.0 | -57.3 | -165.5 | -255.1 | -305.9 | -390.6 | -498.8 | -636.9 | -813.3 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -99.5 | -601.2 | -181.7 | -300.5 | -269.5 | -420.4 | -558.6 | -713.3 | -910.8 | -1,163.0 |
WACC, % | 12.82 | 12.82 | 12.82 | 12.82 | 12.82 | 12.82 | 12.82 | 12.82 | 12.82 | 12.82 |
PV UFCF | ||||||||||
SUM PV UFCF | -2,506.4 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | -1,186 | |||||||||
Terminal Value | -10,960 | |||||||||
Present Terminal Value | -5,995 | |||||||||
Enterprise Value | -8,502 | |||||||||
Net Debt | -264 | |||||||||
Equity Value | -8,238 | |||||||||
Diluted Shares Outstanding, MM | 117 | |||||||||
Equity Value Per Share | -70.31 |
What You Will Get
- Real 10x Genomics Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for 10x Genomics, Inc. (TXG).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates to fit your analysis needs.
- Instant Valuation Updates: Automatic recalculations to assess the impact of changes on 10x Genomics’ fair value.
- Versatile Excel Template: Designed for quick edits, scenario testing, and detailed projections specific to 10x Genomics, Inc. (TXG).
- Time-Saving and Accurate: Avoid building models from scratch while ensuring precision and flexibility in your evaluations.
Key Features
- Comprehensive Data: 10x Genomics’ historical financial statements and pre-filled projections.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: View 10x Genomics’ intrinsic value update instantly.
- Visual Data Representation: Interactive dashboard charts showcase valuation results and essential metrics.
- Designed for Precision: A specialized tool for analysts, investors, and finance professionals.
How It Works
- Download: Get the pre-configured Excel file containing 10x Genomics, Inc.'s (TXG) financial information.
- Customize: Modify projections, such as revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various forecasts and instantly compare results.
- Make Decisions: Utilize the valuation findings to inform your investment approach.
Why Choose This Calculator for 10x Genomics, Inc. (TXG)?
- Accurate Data: Real 10x Genomics financials ensure reliable valuation results.
- Customizable: Adjust key parameters like growth rates, WACC, and tax rates to match your projections.
- Time-Saving: Pre-built calculations eliminate the need to start from scratch.
- Professional-Grade Tool: Designed for investors, analysts, and consultants in the genomics field.
- User-Friendly: Intuitive layout and step-by-step instructions make it easy for all users.
Who Should Use This Product?
- Investors: Evaluate 10x Genomics’ valuation before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation processes and assess future projections.
- Biotech Entrepreneurs: Understand how leading biotech firms like 10x Genomics are valued.
- Consultants: Provide comprehensive valuation reports to clients in the biotech sector.
- Students and Educators: Utilize real-world data to learn and teach valuation methodologies.
What the Template Contains
- Pre-Filled Data: Includes 10x Genomics, Inc.'s historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze 10x Genomics, Inc.'s profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.